A single-arm IIT study of HA131 (hepatic arterial infusion) in combination with systemic therapy (XELOX with or without bevacizumab) as first-Line treatment in gastrointestinal cancer with liver ...

Mutational profiling of appendiceal tumors from diagnostic specimens and circulating tumor DNA. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...

Leaders, innovators and change makers from a breadth of disciplines are being recognized at McMaster’s spring convocation ceremonies for their tremendous accomplishments and contributions to . . .

Oncolytic viruses trigger immunogenic cell death in tumors, releasing signals that activate innate immune cells and promote tumor-specific T-cell responses. While some oncolytic viruses, including FDA ...

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management ...

bDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa K1H 8M5, Canada cDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa K1H 8M5, Canada ...

While T-VEC is the only approved oncolytic virus for melanoma, RP1 appears more potent in early data. 1 The IGNYTE trial (NCT03767348), a phase 1/2, dose-escalation and -expansion study, allowed ...

Candel Therapeutics essentially uses a dual-virus strategy with CAN-2409 and CAN-3110 immunotherapies. Find out why CADL ...

Under the agreement, the company's oncolytic virus candidates ELC-100 and ELC-201 will be included in tests aimed at developing a new type of companion diagnostic to predict the potential success ...

1 Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James’ University Hospital, Leeds, UK Objective ...

Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the success of checkpoint inhibitors in immunotherapy.